Metabolic Characterization and Follow up of Adult Patients Affected by Osteogenesis Imperfecta in Long-term Treatment with Neridronic Acid.
Br J Med Med Res
; 2011 Oct; 1(4): 478-485
Article
em En
| IMSEAR
| ID: sea-162763
ABSTRACT
Aims:
Osteogenesis imperfecta (OI) is a rare inherited disorder causing low bone density and increased fragility. Bisphosphonates (BP) are a treatment of choice for OI. Few studies have investigated the long-term effects of BP in OI patients. Thus, aim of our study was to follow up adults affected by OI to evaluate changes in metabolic, clinical situation and safety of long-term neridronic acid therapy, BP authorized for OI treatment. Studydesign:
Longitudinal observational study. Place and duration of the Study Department of Experimental Medicine, Section of Medical Pathophysiology, Endocrinology and Nutrition. Year 2004 - October 2010.Methodology:
68 patients underwent clinical examination, laboratory endocrine/ metabolic, pro-inflammatory cytokines screening, ECG at baseline and every 3 months and bone mineral density evaluation, by DEXA, once a year.Results:
Skeletal evaluation showed a significant increase of BMD through follow up. Patients were evaluated for metabolic and cardiovascular risk factors, which were unmodified by long-term therapy.Conclusion:
Long-term neridronic acid treatment increases bone density, does not alter metabolic parameters indicating that this therapy can be considered safe and a valid therapeutic option for OI patients.
Texto completo:
1
Índice:
IMSEAR
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Br J Med Med Res
Ano de publicação:
2011
Tipo de documento:
Article